NA Semax Amidate

NA Semax Amidate

NA Semax Amidate

ʻO NA Semax Amidate kahi analog i hoʻolālā ʻia o semax. He N-terminally acetylated a C-terminally amidated derivative o ka Semax peptide, e mālama ana i ke kaʻina kumu.

Pane wikiwiki

Reliable NA Semax Amidate peptide from professional manufacturer and factory. We offer wholesale N-Acetyl Semax Amidate peptides for biomedical laboratory neuroscience and cognitive function research.

SKU: 198886 Māhele:
Kaʻana like i kāu aloha

ʻO NA Semax Amidate kahi analog i hoʻolālā ʻia o ʻaʻole lohe. He N-terminally acetylated a C-terminally amidated derivative o ka Semax peptide, e mālama ana i ke kaʻina kumu.

Hoʻomaikaʻi maikaʻi kēia hoʻololi artificial i ke kūʻē ʻana o ke kaulahao peptide e kūʻē i ka exo- a me nā endopeptidase (laʻana ka leucine aminopeptidase), e hooloihi ana i kona hapalua ola ma kahi o 30 mau minuke i hoʻohālikelike ʻia me ka Semax kumu, me ka lōʻihi o ka hana o 6-12 hola.

Hoʻonui ia i ka paʻa o ka mālama ʻana i ka lumi wela a me ka pono o ka absorption nasal mucosal, ma laila e hōʻoiaʻiʻo ana i ke komo pono ʻana o ka pale koko-lolo (BBB) a me ka hoʻomau mau ʻana i kahi hana kūpono gradient kuʻuna i loko o ka lolo.

Aia kona kumu kumu i ka modulation multi-alanui o ʻōnaeʻa waena hana.

ʻO ka mea mua loa, Hana ʻo NA Semax Amidate ma ke ʻano he upregulator ikaika o kumu neurotrophic no ka lolo (BDNF), ʻo ia ka mea e hoʻonui ai i ke ola neuronal, ulu axonal, synaptic plasticity a potentiation lōʻihi (LTP) - ke kumu molekala no ke aʻo ʻana a me ka hoʻomanaʻo.

Eia kekahi,ʻO NA Semax Amidate ka potentiates dopaminergic, serotonergic, a me ka neurotransmission noradrenergic, ma laila e hoʻonui ai poʻo mua nā hana hoʻokō, me ka nānā ʻana i ke koho a hoʻomanaʻo hana hiki.

Hōʻike pū ʻo NA Semax Amidate i nā hopena neuroprotective koʻikoʻi ma ke kāohi ʻana i ka hoʻokuʻu cytokine inflammatory, e hoemi ana i ka poino oxidative stress, a me ka hoʻopaʻa ʻana i ka hiki o ka membrane mitochondrial.

He kūpono ia e kūʻē i nā ʻano ʻino pathological e like me ischemia lolo, hypoxia, ʻehaʻeha, a neurodegeneration.

Ua ʻae ʻia ma Rūsia ma ke ʻano he adjunctive therapy no ka acute hahau, ʻeha lolo ʻeha, a me ka pae mua ʻO ka maʻi o Parkinson.

Ma ka hōʻuluʻulu, Hoʻohana ʻo NA Semax Amidate i nā hoʻololi kemika e lanakila ai i nā palena o ka peptide kūlohelohe, ma laila ua ʻoi aku ma mua o ka Semax maʻamau i loko hoonui noonoo, neuroprotection, hoʻoponopono manaʻo, a me ka hooponopono eha.

He koʻikoʻi koʻikoʻi kēia no ka mālama ʻana o nā maʻi neurodegenerative a me ka hoʻoikaika ʻana i ka hoʻihoʻi ʻana i ka hana o ke kikowaena.

Kaʻina

AC-me-glu-his-phe-pro-gly-pro-nh2

Helu CAS

/

ʻĀpana Molekala

C39H54N10O10S

Kaumaha Molekala

854.98

Noiʻi o NA Semax Amidate

Hōʻike ʻo NA Semax Amidate i ka maikaʻi e hoʻohālikelike ʻia me ka maʻamau anxiolytic nā lāʻau lapaʻau i kekahi mau ʻano preclinical.

1.Hoʻonui i ka naʻau a me ka neural plasticity

Hoʻopau ʻo NA Semax Amidate i ka mea transcription CREB, hooponopono BDNF hōʻike gene a me ka hoʻonui ʻana i nā pae neuronal BDNF ma o ka nui 40%.

Hoʻolaha kēia iwi kuamoʻo dendritic hoʻokumu ʻana, alakaʻi axonal, a me ka hōʻuluʻulu o ka postsynaptic density protein 95 (PSD-95), ma laila e hoʻonui ai i ka hiki ke aʻo.

Hōʻike nā hoʻokolohua hoʻohālikelike olaola a 35-50% ka hoʻomaikaʻi ʻana i ka nui o ka mālama ʻana i ka hoʻomanaʻo ma ka pōʻaiapili makaʻu hoʻoluʻu nā hoʻokolohua.

ʻāpana lolo electrophysiological hoʻopaʻa hoʻopaʻa ʻia i hoʻonui ʻia LTP amplitude a me ka lōʻihi, e hōʻike ana ua hoʻololi hou ʻo NA Semax Amidate synaptic plasticity nā paepae ma o ka hoʻoikaika hohonu o ka kumu neurotrophic pūnaewele.

2.Neuroprotection a me ka Hoʻoponopono

Hoʻopau ʻo NA Semax Amidate i ka adenylate cyclase (AC)-ʻO ke ala cAMP-PKA e hoʻopaʻa mitochondrial hiki i ka membrane, kaohi cytochrome C hoʻokuʻu, a ke kāohi nei caspase-3 cascade activation, ma laila e ālai ana i ka hana hoʻokō o apoptosis.

I ka manawa like, hooponopono ia superoxide dismutase hōʻike a keʻakeʻa i ka ʻeha nui cytokine hana ʻana.

I ka iole ʻaʻaʻa lolo waena kumu hoʻohālike occlusion, ua emi iho ʻehaʻeha o ka lolo leo ma ka oi 50%.

Ma kahi MPTP kumu hoʻohālike o ka maʻi o Parkinson, ua mahuahua dopaminergic ola neuron e 35%, e hōʻike ana i ka neuroprotection ikaika.

3.Nā hopena anxiolytic a me analgesic

Hoʻonui ka NA Semax Amidate i ka pilina no ka endogenous nā enkephalins a β-endorphin oiai e keakea ana G protein-coupled receptor kinase (HELENE)-ka hoʻopili ʻana o ka mea hoʻokipa i loko a me ka desensitization, pela e hooloihi ana analgesic hōʻailona.

Hoʻemi pū ia i ka hypersensitivity ʻehaʻeha o ka FTO.

I nā hiʻohiʻona ʻiole, nā paepae ʻeha ua hookiekieia e 30-40% a ua hookiekieia no 4 i 6 hola.

I ka ʻeha constriction mau (CCI) nā hiʻohiʻona, mechanical alodynia ua hoʻomāmā ʻia e 50%, e hōʻoia hou ana i nā waiwai anti-stress a me ka hoʻokūpaʻa ʻana o ka NA Semax Amidate.

Hōʻike ʻo NA Semax Amidate i ka maikaʻi e like me nā lāʻau anxiolytic maʻamau i nā hiʻohiʻona preclinical..

4.Hoʻonui i ka naʻau a me ka neural plasticity

Hoʻopau ʻo NA Semax Amidate i ka helu transcription CREB, upregulating BDNF gene expression a me ka hoonui neuronal BDNF pae ma ka oi 40%.

Hoʻoikaika kēia i ka hoʻokumu ʻana o ka spine dendritic, alakaʻi axonal, a me ka hōʻuluʻulu o ka postsynaptic density protein 95 (PSD-95), ma laila e hoʻonui ai i ka hiki ke aʻo.

Hōʻike nā hoʻokolohua hoʻohālikelike olaola a 35-50% ka hoʻomaikaʻi ʻana i ka nui o ka mālama ʻana i ka hoʻomanaʻo i nā hoʻokolohua hoʻoweliweli makaʻu.

Hoʻopaʻa ʻia nā hoʻopaʻa leo electrophysiological ʻāpana lolo i ka nui o ka LTP amplitude a me ka lōʻihi, e hōʻike ana ua hoʻololi hou ʻo NA Semax Amidate i nā paepae plasticity synaptic ma o ka hoʻōla hohonu ʻana o ka ʻoihana neurotrophic factor..

5.Neuroprotection a me ka Hoʻoponopono

Hoʻopau ʻo NA Semax Amidate i ka adenylate cyclase (AC)-ʻO ke ala cAMP-PKA e hoʻopaʻa i ka hiki o ka membrane mitochondrial, pale i ka hoʻokuʻu cytochrome C, a hoʻopaʻa i ka caspase-3 cascade activation, e ālai ana i ka hana hoʻokō o ka apoptosis.

I ka manawa like, Hoʻoponopono ia i ka hōʻike superoxide dismutase a kāohi i ka hana cytokine inflammatory nui.

I loko o ka ʻiole i waena o ke aʻa o ke aʻaʻa occlusion model, ua hoʻemi ʻia ka nui o ka cerebral infarction 50%.

Ma kahi hoʻohālike MPTP o ka maʻi o Parkinson, ua hoʻonui i ke ola dopaminergic neuron e 35%, e hōʻike ana i ka neuroprotection ikaika.

6.Nā hopena anxiolytic a me analgesic

Hoʻonui ʻo NA Semax Amidate i ka pilina no nā enkephalins endogenous a me β-endorphin ʻoiai ke kāohi nei i ka G protein-coupled receptor kinase. (HELENE)-ka hoʻopili ʻana o ka mea hoʻokipa i loko a me ka desensitization, ma laila e hoʻolōʻihi ai i ka hōʻailona analgesic.

Hoʻemi pū ia i ka hypersensitivity ʻehaʻeha o ka FTO.

I nā hiʻohiʻona ʻiole, ua hookiekieia na paepae eha e 30-40% a ua hookiekieia no 4 i 6 hola.

I ka ʻeha constriction mau (CCI) nā hiʻohiʻona, Ua hoʻemi ʻia ka mechanical allodynia e 50%, e hōʻoia hou ana i nā waiwai anti-stress a me ka hoʻokūpaʻa ʻana o ka NA Semax Amidate.

COA

HPLC

MS

(1) ʻO Dmitrieva, V. ʻO G.; Povarova, O. V.; Skvortsova, V. I.; Limborska, S. A.; Myasoedov, N. F.; Dergunova, L. V. Hoʻopau ʻo Semax a me Pro-Gly-Pro i ka Transcription o Neurotrophins a me kā lākou Receptor Genes ma hope o Cerebral Ischemia. Cellular a me Molecular Neurobiology 2009, 30 (1), 71-79. DOI: 10.1007/s10571-009-9432-0.

(2) ʻEremina, K. O.; Kudrin, V. S.; Saransari, P.; Huahana, S. S.; ʻO Grivennikov, I. A.; Myasoedov, N. F.; ʻO Rayevsky, K. S. Mai hoʻolohe, He ACTH(4-10) Analogue me Nootropic Properties, Hoʻoulu i nā ʻōnaehana lolo Dopaminergic a me Serotoninergic i nā Rodents. ʻImi ʻImi Neurochemical 2005, 30 (12), 1493-1500. DOI: 10.1007/s11064-005-8826-8.

(3) ʻO Glazova, N. Y.; Manchenko, ʻO D. M.; Volodina, M. A.; Merchieva, S. A.; Andreeva, L. A.; Kudrin, V. S.; Myasoedov, N. F.; Levitskaya, N. ʻO G. Mai hoʻolohe, synthetic ACTH(4–10) analogue, Hoʻopau i nā loli a me nā neurochemical ma hope o ka hoʻolaha ʻana o ka fluvoxamine i ke ola mua i nā ʻiole keʻokeʻo. Nā neuropeptides 2021, 86. DOI: 10.1016/j.npep.2020.102114.

(4) Koina, N. V.; Sokolov, O.; Gabaeva, M. V.; ʻO Grivennikov, I. A.; Andreeva, L. A.; Miasoedov, N. F.; Zozulia, A. A. [Hoʻopaʻa ʻo Semax a me selank i ka enkephalin-degrading enzymes mai ka serum kanaka]]. Bioorg Khim 2001, 27 (3), 180-183. DOI: 10.1023/a:1011373002885 Mai ka NLM Medline.

(5) Medvedeva, E. V.; ʻO Dmitrieva, V. ʻO G.; Limborska, S. A.; Myasoedov, N. F.; Dergunova, L. V. Mai hoʻolohe, he analog o ACTH(4−7), hoʻoponopono i ka hōʻike ʻana o nā genes pane pale i ka wā ʻeha lolo ischemic i nā ʻiole. Molecular Genetics a me Genomics 2017, 292 (3), 635-653. DOI: 10.1007/s00438-017-1297-1.

(6) Pae, C.-U. Hiki i ka Therapeutic o "Semax" no ke kaumaha. CNS Spectrums 2014, 13 (1), 20-21. DOI: 10.1017/s1092852900016102.

(7) ʻO Vlasova, I. M.; Buravtcov, ʻO D. E.; Saletsky, A. M. Ka nānā ʻana o ka luminescence o nā ʻāpana koko i nā haʻawina o nā waiwai neuroprotective o ka lāʻau "Semax" i ka cerebral ischemia. Nūpepa o Applied Spectroscopy 2009, 76 (1), 121-126. DOI: 10.1007/s10812-009-9141-y.

Kaʻina:

AC-me-glu-his-phe-pro-gly-pro-nh2

CAS:

/

M.W:

854.98 g/mol

Home Huli Whatsapp Nā lawelawe Huahana